Summary
Metabolites are small molecules that are useful for estimating disease risk and elucidating disease biology. Nevertheless, their causal effects on human diseases have not been evaluated comprehensively. We performed two-sample Mendelian randomization to systematically infer the causal effects of 1,099 plasma metabolites measured in 6,136 Finnish men from the METSIM study on risk of 2,099 binary disease endpoints measured in 309,154 Finnish individuals from FinnGen. We identified evidence for 282 causal effects of 70 metabolites on 183 disease endpoints (FDR<1%). We found 25 metabolites with potential causal effects across multiple disease domains, including ascorbic acid 2-sulfate affecting 26 disease endpoints in 12 disease domains. Our study suggests that N-acetyl-2-aminooctanoate and glycocholenate sulfate affect risk of atrial fibrillation through two distinct metabolic pathways and that N-methylpipecolate may mediate the causal effect of N6, N6-dimethyllysine on anxious personality disorder. This study highlights the broad causal impact of plasma metabolites and widespread metabolic connections across diseases.
Competing Interest Statement
E.B.F. is an employee and stockholder of Pfizer. The remaining authors declare no competing interests.
Funding Statement
This work was supported by the National Institutes of Health (NIH) under awards U01 DK062370 (M.B.), R35 GM138121 (X.Q.W.), R01 DK119380 (X.Q.W.), the American Diabetes Association Postdoctoral Fellowship (1-19-PDF-061, X.Y.), the University of Michigan Precision Health Scholarship (X.Y.), the Academy of Finland under grant no. 321428 (M.L.), the Sigrid Juselius Foundation (M.L.), the Academy of Finland Center of Excellence in Complex Disease Genetics under grant no. 312062 and 336820 (S.R.), grant no. 312074 and 336824 (A.P.), the Finnish Foundation for Cardiovascular Research (S.R.), University of Helsinki HiLIFE Fellow and Grand Challenge grants, and Horizon 2020 Research and Innovation Programme (grant no. 101016775, INTERVENE) (S.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
FinnGen genome-wide summary statistics are available at https://r7.finngen.fi. Full summary statistics from the genome-wide association studies of the 1,099 plasma metabolites are available at https://pheweb.org/metsim-metab/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
FinnGen genome-wide summary statistics are available at https://r7.finngen.fi. Full summary statistics from the genome-wide association studies of the 1,099 plasma metabolites are available at https://pheweb.org/metsim-metab/.
